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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
1. To examine the effects of behavioural activation compared to all other psychological therapies for acute depression in adults.
2. To examine the effects of behavioural activation compared to all medication for acute depression in adults.
3. To examine the effects of behavioural activation compared to treatment as usual/ waiting list/ attention placebo/ psychological
placebo control conditions for acute depression in adults.
B A C K G R O U N D
Description of the condition
Depression, when diagnosed in a clinical setting, most often refers
to major depressive disorder. It is characterised by a period of at
least twoweeks of depressedmood, or a persistent loss of interest or
pleasure in activities which were previously considered enjoyable,
or both (APA 2013). A range of symptoms may accompany these
key features of depression, including weight loss or weight gain,
insomnia or hypersomnia, psychomotor agitation or retardation,
fatigue, loss of energy, feelings of excessive guilt and worthlessness,
diminished concentration, and recurrent thoughts of death (APA
2013).
Depression is the fifth global cause of disease burden in terms of
years lived with a disability (YLD), and was ranked in the top ten
of YLD in 191 out of 195 countries worldwide (Vos 2017). In
2014, 7.1% of the population living in the 28 countries of the
European Union was estimated to report depression, with higher
rates reported by women and by Europeans living in cities. Preva-
lence rates of self-reported depression varied from 4% in 15- to
24-year-olds to 10% in those aged 75 and over (Eurostat 2014).
Depression has a long-lasting impact on patients, their families,
andwider society. It is associatedwithmarkedpersonal and societal
economic losses due to healthcare costs for mental and comorbid
physical healthcare, reduced productivity in the workplace, and
years of life lost (Greenberg 2015). Ameta-analysis of data from35
countries found a 52% increased risk of mortality, after adjusting
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for publication bias (Cuijpers 2014).
Description of the intervention
Clinical guidelines recommend pharmacological and psycholog-
ical interventions, alone or in combination, in the treatment of
mild to moderate depression (NICE 2009).
The prescribing of antidepressants has increased dramatically in
many Western countries over the past 20 years, mainly with the
advent of selective serotonin reuptake inhibitors and other agents
such as serotonin-noradrenaline reuptake inhibitors (SNRIs) and
noradrenalinergic and specific serotonergic antidepressants (NaS-
SAs) (Ilyas 2012). Antidepressants remain the mainstay of treat-
ment for moderate to severe depression in healthcare settings,
whereas for subthreshold depressive symptoms ormild depression,
low-intensity psychosocial therapy and psychological therapies are
recommended (NICE 2009).
Whilst antidepressants are of proven efficacy for the acute treat-
ment of depression (Arroll 2009; Cipriani 2005; Cipriani 2009a;
Cipriani 2009b; Cipriani 2009c; Guaiana 2007), adherence rates
remain very low (Hunot 2007; van Geffen 2009), in part because
of patients’ concerns about side effects and possible dependency
(Hunot 2007). Furthermore, surveys consistently demonstrate pa-
tients’ preference for psychological therapies over treatment with
antidepressants (Churchill 2000; McHugh 2013; Riedel-Heller
2005). Therefore, psychological therapies offer an important al-
ternative or adjunctive intervention for depressive disorders.
A diverse range of psychological therapies is available for the treat-
ment of depression. Psychological therapies may be broadly cat-
egorised into four separate philosophical and theoretical schools,
comprising psychoanalytic/dynamic (Freud 1949; Jung 1963;
Klein 1960), behavioural (Skinner 1953; Watson 1924; Wolpe
1958), humanistic (Maslow 1943; May 1961; Rogers 1951), and
cognitive approaches (Beck 1979; Lazarus 1971). Each of these
four schools incorporates several different and overlapping psy-
chotherapeutic approaches. Some psychotherapeutic approaches,
such as cognitive-analytic therapy (CAT) (Ryle 1990), explic-
itly integrate components from several theoretical schools. Other
approaches, such as interpersonal therapy (IPT) for depression
(Klerman 1984), have been developed to address characteristics
considered specific to the disorder of interest.
Behavioural therapy is a term that has been used to describe a
broad range of therapies using principles of operant conditioning,
in which behaviours are modified through learning. It became a
dominant force in the 1950s, drawing on the work of Skinner
1953, Wolpe 1958, and Eysenck 1960. Behavioural therapy em-
phasises the role of environmental cues in influencing the acquisi-
tion and maintenance of behaviours (Nelson-Jones 1990) and, in
contrast with psychoanalysis, was developed through experimen-
tally derived principles of learning (Rachman 1997).
With the advent of cognitive therapy in the 1970s, behavioural
therapy approaches based purely on operant (learning from the
consequences of behaviours) and respondent (responsive be-
haviour as a result of a stimulus) principles became regarded as
insufficient. However, the interest in the feasibility of behavioural
treatments for depression has since been renewed (Dimidjian
2011; Ekers 2014; Hopko 2003a). The term behavioural activa-
tion appears to have been used for the first time in 1990, as a
description of the behavioural components in cognitive therapy
(Hollon 1990). Jacobson showed that the behavioural compo-
nent of cognitive-behavioural therapy (CBT) was as effective as
the full package of CBT, and investigators developed a new and
more comprehensive model of behavioural activation that would
be amenable to dissemination (Jacobson 1996; Jacobson 2001).
It would appear that behavioural activation has now become the
commonly adopted description, and we will use this term in the
rest of this review to refer to the intervention (Martell 2010).
How the intervention might work
Skinner proposed that depression was associated with an interrup-
tion in established sequences of healthy behaviour that were pre-
viously positively reinforced by the social environment and were
based on operant conditioning principles (in which behaviour pat-
terns are learnt, rather than instinctive; Skinner 1953). In subse-
quent expansions of this model, reduction of positively reinforced
healthy behaviours has also been attributed to a decrease in the
number and range of reinforcing stimuli available to the individ-
ual, lack of skill in obtaining positive reinforcement (Lewinsohn
1974), increased frequency of punishment, or a combination of
two or all of these (Lewinsohn 1984).
Behavioural activation can be defined as a brief psychotherapeutic
approach that seeks to change the way a person interacts with their
environment, aiming to:
1. increase access to positive reinforcers of healthy behaviours;
2. reduce avoidance behaviours that limit access to positive
reinforcement;
3. understand and address barriers to activation.
Treatments are collaborative and focused on the present. Many
differing techniques are incorporated into treatment; however all
use self-monitoring of a mood-environment link and scheduling
of new or adaptive behaviours to meet targets (Kanter 2010). In
doing so, the therapy helps people tomake contactwith potentially
reinforcing experiences (Jacobson 2001).
The original model of behavioural activation, developed by Jacob-
son, was defined primarily by the elimination of cognitive inter-
vention elements (Dimidjian 2006). On the basis of its original
design, behavioural activation model components commonly in-
clude developing a shared treatment rationale; increasing access
to pleasant events, activities, and consequences; activity schedul-
ing and developing social skills self-monitoring links between be-
haviour and mood; and activity scheduling to promote contact
with sources of positive reinforcement from the person’s environ-
ment. In some cases the use of some form of problem-solving or
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functional analysis is added to overcome any potential barriers to
the scheduling of activities. No attempt is made to directly re-
structure cognitions, however the exploration of the consequence
of rumination in restricting access to positive reinforcement is a
common focus of the approach.
Why it is important to do this review
According to the clinical guidelines produced by the National
Institute forHealth andClinical Excellence, behavioural activation
is one of the recommended treatment options for subthreshold
depressive symptoms, mild to moderate depression, and severe
depression, along with CBT and IPT. However, the guidelines
acknowledge that evidence for behavioural activation is currently
less robust than for the other recommended therapies (NICE
2009).
The effects of behavioural therapies for depression versus other
psychological therapies were previously examined in a Cochrane
Review, which reported that low- to moderate-quality evidence
from 25 trials suggested that behavioural therapies and other psy-
chological therapies were equally effective (Shinohara 2013). This
Cochrane Review did not cover trials comparing behavioural ther-
apy to treatment as usual, nor did it include the emerging litera-
ture on new treatment models of behavioural activation.
Two Cochrane Reviews of ’third wave’ cognitive and behavioural
therapies, one comparing the intervention to treatment as usual
and one comparing to other therapies, identified three trials of
behavioural activation for depression (Churchill 2013; Hunot
2013). The small number of trials together with the low quality
of the evidence limited the ability to draw any conclusions on
effectiveness. Another systematic review of behavioural activation
found evidence from26 trials, most of them lowquality, indicating
that behavioural activation is more effective than a wide range of
control treatments, including medication (Ekers 2014).
There is no Cochrane Review that includes all behavioural acti-
vation therapies currently recommended for the treatment of de-
pression. Behavioural activation is increasingly receiving attention
as a potentially cost-effective intervention for depression, which
may be easier to deliver and implement than other psychological
therapymodels (Richards 2016). Given this resurgence of interest,
a comprehensive review of the comparative effectiveness and ac-
ceptability of behavioural activation interventions for depression
is now timely to inform and update clinical practice and future
clinical guideline development.
O B J E C T I V E S
1. To examine the effects of behavioural activation compared
to all other psychological therapies for acute depression in adults.
2. To examine the effects of behavioural activation compared
to all medication for acute depression in adults.
3. To examine the effects of behavioural activation compared
to treatment as usual/ waiting list/ attention placebo/
psychological placebo control conditions for acute depression in
adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were eligible for inclusion in
this review. We included trials employing a cross-over design in
the review (whilst we acknowledge that this design is rarely used
in psychological therapy trials), but we only used data from the
first active treatment phase. Cluster-RCTs were also eligible for
inclusion.
Quasi-randomised controlled trials, in which treatment assign-
ment is decided through methods such as alternate days of the
week, were not eligible for inclusion. We included trials that re-
placed dropouts without randomisation only when the proportion
of replaced participants was less than 20%.
Types of participants
Participant characteristics
Trials of men and women aged 18 years and over are eligible for
inclusion. We will exclude trials that contain participants under
18 years of age.
Setting
Trials could be conducted in a primary, secondary or community
setting. We will exclude trials involving inpatients. We will in-
clude trials that focus on specific populations - nurses, care givers,
depressed participants at a specific workplace - if all participants
meet the criteria for depression. Nursing homes in this review are
considered outpatient settings, as they are places of residence.
Diagnosis
We will include all trials that focused on acute phase treatment of
clinically diagnosed depression or subthreshold depression.
1. We will include trials adopting any standardised diagnostic
criteria to define participants suffering from an acute phase
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unipolar depressive disorder. Accepted diagnostic criteria include
Feighner criteria, Research Diagnostic Criteria and criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Third
Edition ((DSM-III); APA 1980), DSM-III-Revised ((R); APA
1987),DSM-Fourth Edition ((IV); APA 1994), DSM-IV-Text
Revision ((TR); APA 2000), DSM-5 (APA 2013), and
International Classification of Diseases, Tenth Edition ((ICD-10);
WHO 1992). Earlier trials may have used ICD-Ninth Edition
((ICD-9); WHO 1978), but ICD-9 is not based on
operationalised criteria, so we will exclude trials using ICD-9
from this category.
2. To fully represent the broad spectrum of severity of
depressive symptoms encountered by healthcare professionals in
primary care, we will include trials that used non-operationalised
diagnostic criteria or a validated clinician or self-report
depression symptom questionnaire, such as the Hamilton Rating
Scale for Depression (Hamilton 1960), or the Beck Depression
Inventory (Beck 1961), to identify depression cases as based on a
recognised threshold.
3. Subthreshold depression, also called subsyndromal,
subclinical, or minor depression. We will accept any trials that
established subthreshold depression based on the above
diagnostic criteria or validated depression symptom
questionnaires.
When possible, we will use accepted strategies for classifying mild,
moderate and severe depression on the basis of criteria used in the
evidence syntheses underpinning the NICE 2009 guidelines for
depression. NICE 2009 defines severity of depression in accor-
dance with DSM-5 as follows: mild depression: few, if any, symp-
toms in excess of the five required to make the diagnosis, with
symptoms resulting in only minor functional impairment. Mod-
erate depression: symptoms of functional impairment between
’mild’ and ’severe’. Severe depression: most symptoms, andmarked
interference of the symptoms with functioning. Can occur with
or without psychotic symptoms.
We will exclude from the review trials focusing on chronic depres-
sion or treatment-resistant depression (i.e. trials that list these con-
ditions as inclusion criteria). We will also exclude trials in which
participants were receiving treatment to prevent relapse after a de-
pressive episode (i.e. where participants were not depressed at trial
entry).
If participants meet the criteria for depression or subthreshold
depression as stated above, wewill include trials of people described
as ‘at risk of suicide’ or with dysthymia or other affective disorders
such as panic disorder, but otherwise we will exclude these trials.
We will not include subgroup analyses of people with depression
selected from people with mixed diagnoses because such trials
would be susceptible to publication bias (the trial authors reported
such subgroup trials because the results were ’interesting’). In other
words, we will include these trials only if the inclusion criteria for
the entire trial satisfies our eligibility criteria.
Comorbidity
Trials involving participants with comorbid physical or common
mental disorders are eligible for inclusion as long as the comor-
bidity is not the focus of the trial. For example, we will exclude
trials that focus on depression among individuals with Parkinson’s
disease or after acute myocardial infarction but accept trials that
may have included some participants with Parkinson’s disease or
with acute myocardial infarction.
Types of interventions
Experimental interventions
A previously published Cochrane Review for behavioural therapy
in depression provided a framework for psychological therapies,
including behavioural therapy (Shinohara 2013). Given recent de-
velopments in literature and practice regarding behavioural acti-
vation approaches, we consider behavioural activation as part of
behavioural therapies, rather than being classified as a ’third wave’
therapy. In line with the behavioural therapy review, we created
the comparator categories of psychological therapies on the ba-
sis of both treatment approach (e.g. their theoretical background
and the manuals they used) and content (what therapeutic tech-
niques they mainly used or what was their area of focus). See also
Appendix 1.
Behavioural activation
We will include trials evaluating treatment approaches for de-
pression that are either explicitly called ’behavioural activation’,
or treatments that are described using the main elements of be-
havioural activation for depression, such as pleasant events and ac-
tivities, activity scheduling, positive reinforcement from the envi-
ronment, positive interaction or re-engagement with the environ-
ment. This means that we will include behavioural therapies in the
treatment group as long as they are described using the main ele-
ments of behavioural activation. Interventions that contain some
elements of behavioural therapy, such as CBT or problem-solving
therapy, are not eligible for inclusion.
Format of psychological therapies
Therapies delivered by therapists of all levels are eligible for in-
clusion. This includes psychologists or psychotherapists accred-
ited by a professional body for psychology or psychotherapy, who
completed formal training to deliver psychological therapies, as
well as lay counsellors and non-specialist therapists who have been
specifically trained to deliver treatment according to a behavioural
activation protocol.
We will include computerised and self-help interventions if they
were facilitated by a qualified practitioner. This means at least
some element of interaction with a qualified facilitator is required.
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Psychological therapies conducted on an individual or group basis
are eligible for inclusion.
The number of sessions is not limited, and we accept psychological
therapies delivered in only one session.
Comparators
All comparators are accepted as long as they are not a type of be-
havioural activation. We categorise psychological therapies as be-
havioural therapy, social skills training/assertiveness training, re-
laxation therapy, CBT, third wave CBT, psychodynamic, human-
istic and integrative approaches.
Behavioural therapy
If we identify any behavioural therapies that do not contain the
main elements of behavioural activation, we will include them as
comparators.
Social skills training/assertiveness training
The social skills trainingmodel (SST) proposes that depressed peo-
ple may have difficulty initiating, maintaining and ending conver-
sations (Jackson 1985). Because of these deficits, the individual is
unable to elicit mutually reinforcing behaviour from other people
in his or her environment. SST subsumes assertion and conversa-
tional skills, together withmore specialised subskills such as dating
and job interview skills. Different social contexts may be targeted,
for example interaction with friends, family members, people at
school, or at work, and interventions such as instruction, mod-
elling, rehearsal, feedback and reinforcement are used to enable
the development of new responses (Jackson 1985). As assertive-
ness training represents a key component of SST, we included it
in the SST category.
Relaxation therapy
Relaxation training is a behavioural stress management technique
that induces a relaxation response, helping to switch off the fight/
flight response and causing levels of stress hormones in the blood-
stream to fall. A variety of techniques may be used to induce relax-
ation, the most common of which is Jacobson’s progressive muscle
relaxation training (Bernstein 1973).
Cognitive-behavioural therapies (CBTs)
In CBT, therapists aim to work collaboratively with patients to
understand the link between thoughts, feelings and behaviours,
and to identify and modify unhelpful thinking patterns, underly-
ing assumptions and idiosyncratic cognitive schemata about the
self, others and the world (Beck 1979). Cognitive change meth-
ods for depression are targeted at the automatic thought level in
the first instance and include thought catching, reality testing and
task assigning as well as generating alternative strategies (Williams
1997). Behavioural experiments are then used to re-evaluate un-
derlying beliefs and assumptions (Bennett-Levy 2004). We cate-
gorised these therapies into six subcategories: cognitive therapy,
rational emotive behaviour therapy, problem-solving therapy, self-
control therapy, a coping with depression course and other CBTs.
’Third wave’ cognitive and behavioural therapies (third wave
CBTs)
Third wave CBT approaches conceptualise cognitive thought pro-
cesses as a form of ’private behaviour’ (Hayes 2006; Hofmann
2008). Third wave CBTs target the individual’s relationship with
cognitions and emotions, focusing primarily on the function of
cognitions, such as thought suppression or experiential avoid-
ance (an attempt or desire to suppress unwanted internal experi-
ences, such as emotions, thoughts andbodily sensations (Hofmann
2008)). A range of strategies, including mindfulness exercises, ac-
ceptance of unwanted thoughts and feelings and cognitive dif-
fusion (stepping back and seeing thoughts as just thoughts), are
used to bring about change in the thinking process. Drawing
from psychodynamic and humanistic principles, third wave CBT
approaches place great emphasis on use of the therapeutic rela-
tionship. We categorised these therapies into subcategories: ac-
ceptance and commitment therapy, compassionate mind training,
functional analytic psychotherapy, metacognitive therapy, mind-
fulness-based cognitive therapy, dialectical behaviour therapy and
other third wave CBTs.
Psychodynamic therapies
Grounded in psychoanalytic theory (Freud 1949), psychodynamic
therapy (PD) uses the therapeutic relationship to explore and re-
solve unconscious conflict through transference and interpreta-
tion, with development of insight and circumscribed character
change as therapeutic goals, and relief of symptoms as an indirect
outcome. Brief therapy models have been devised byMalan 1963,
Mann 1973 and Strupp 1984. We categorised these therapies
into four subcategories: drive/structural model (Freud), relational
model (Strupp, Luborsky), integrative analytic model (Mann) and
other psychodynamic therapies.
Humanistic therapies
Contemporary models of humanistic therapies differ from one
another somewhat in clinical approach, but all focus attention on
the therapeutic relationship (Cain 2002), within which therapist
‘core conditions’ of empathy, genuineness and unconditional pos-
itive regard (Rogers 1951), are regarded as cornerstones for fa-
cilitating client insight and change. We categorised these thera-
pies into seven subcategories: person-centred therapy (Rogerian),
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gestalt therapy, experiential therapies, transactional analysis, exis-
tential therapy, non-directive/supportive therapies and other hu-
manistic therapies.
Interpersonal, cognitive analytic and other integrative
therapies
Integrative therapies are approaches that combine components of
different psychological therapy models. Integrative therapy mod-
els include interpersonal therapy (IPT) (Klerman 1984), cognitive
analytic therapy (CAT; (Ryle 1990)), and Hobson’s conversational
model (Hobson 1985), manualised as psychodynamic interper-
sonal therapy (Shapiro 1990). With its focus on the interpersonal
context, IPT was developed to specify what was thought to be
a set of helpful procedures commonly used in psychotherapy for
depressed outpatients (Weissman 2007), drawing in part from at-
tachment theory (Bowlby 1980), and cognitive-behavioural ther-
apy within a time-limited framework. CAT, also devised as a time-
limited psychotherapy, integrates components from cognitive and
psychodynamic approaches. The conversational model integrates
psychodynamic, interpersonal and person-centred model compo-
nents.
Counselling interventions traditionally draw from a wide range
of psychological therapy models, including person-centred, psy-
chodynamic and cognitive-behavioural approaches, applied inte-
gratively, according to the theoretical orientation of practitioners
(Stiles 2008). Therefore, we will usually include trials of coun-
selling with integrative therapies. However, if the counselling in-
tervention consists of a single discrete psychological therapy ap-
proach, we will categorise it as such, even if the intervention is
referred to as ’counselling’. If the intervention is manualised, this
will inform our classification.
Motivational interviewing and other forms of integrative therapy
approaches are also included in this category.
Waiting list
Participants are randomly assigned to the active intervention group
or control group, and they will either receive the intervention first
or be assigned to a waiting list until all participants in the inter-
vention group have received the intervention. During the course
of the trial, people on the waiting list can receive any appropriate
medical care.
Attention placebo
We define this as a control condition that is regarded as inactive
by both researchers and participants in a trial.
Psychological placebo
We define this as a control condition in a trial that is regarded
by researchers as inactive but is regarded by participants as active
(also called placebo therapy or sham treatment).
Medication
All medication prescribed with the goal to treat depression, most
commonly antidepressants; any dose, route of administration, du-
ration, and frequency.
Medical placebo
All types of medical placebos or ’sugar pills’.
No treatment
Trial participants not receiving any treatment for depression dur-
ing the course of the trial.
Excluded interventions
We will exclude from the review trials of long-term, continuation
or maintenance therapy interventions designed to prevent relapse
of depression or to treat chronic depressive disorders. Similarly,
we will exclude trials of interventions designed to prevent a future
episode of depression. Postnatal depression is considered a separate
condition with contributing factors distinct frommajor depressive
disorder, and we therefore excluded it.
We excluded psychological therapy models based on social con-
structionist principles (that focus on the ways in which individ-
uals and groups participate in the construction of their perceived
social reality), including couples therapy, family therapy, solution-
focused therapy (de Shazer 1988), narrative therapy, personal con-
struct therapy, neuro-linguistic programming and brief problem
solving (Watzlavick 1974). These therapies work with patterns
and dynamics of relating within and between family, social and
cultural systems to create a socially constructed framework of ideas
(O’Connell 2007), rather than focusing on an individual’s reality.
A previously published Cochrane Review on couples therapy for
depression has recently been updated (Barbato 2018), and a review
of family therapy for depression is to be updated (Henken 2007).
Types of outcome measures
Primary outcomes
1. Treatment efficacy: the number of participants who
responded to treatment, as determined by changes in scores for
Beck Depression Inventory (BDI; Beck 1961), Hamilton Rating
Scale for Depression (HAM-D; Hamilton 1960), or
Montgomery-Asberg Depression Rating Scale (MADRS;
Montgomery 1979), or in scores from any other validated
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depression scale. Many trials define response as 50% or greater
reduction on BDI, HAM-D, etc., with some trials defining
response using Jacobson’s Reliable Change Index; we accepted
the trial authors’ original definition. If the original authors
reported several outcomes corresponding with our definition of
response, we calculated and reported the standardised mean
difference of all measures used.
2. Treatment acceptability: the number of participants who
dropped out of psychological therapy for any reason
Secondary outcomes
1. Improvement in depression symptoms, based on a
continuous outcome of group mean scores at the end of
treatment using BDI, HAM-D, MADRS or any other validated
depression scale
2. Quality of life, as assessed with the use of validated
measures such as Short Form (SF)-36 ( Ware 1993), Health of
the Nation Outcome Scales (HoNOS; Wing 1994), EuroQol
(Brooks 1995), and World Health Organization Quality of Life
(WHOQOL; WHOQL 1998)
3. Social adjustment and social functioning, including Global
Assessment of Function ( Luborsky 1962) scores
4. Improvement in anxiety symptoms, as measured using a
validated continuous scale, either assessor-rated, such as the
Hamilton Anxiety Scale (HAM-A) (Hamilton 1959), or self-
report, including the Trait subscale of the Spielberger State-Trait
Anxiety Inventory (STAI-T) (Spielberger 1983), and the Beck
Anxiety Inventory (BAI) (Beck 1988)
5. Adverse effects, such as counts of completed suicides,
attempted suicides, or worsening of symptoms were summarised
in narrative form.
Search methods for identification of studies
Electronic searches
TheCochraneCommonMentalDisorders’ Information Specialist
will conduct searches on the following bibliographic databases us-
ing relevant subject headings (controlled vocabularies) and search
syntax, appropriate to each resource. The search strategies will be
designed to identify RCTs of ’behavioural activation’, or the main
elements of behavioural activation for depression in participants
with clinically diagnosed depression or subthreshold depression.
• Cochrane Common Mental Disorders Trials Register
(CCMD-CTR); all available years (Appendix 2);
• Cochrane Central Register of Controlled Trials
(CENTRAL; current issue);
• Ovid MEDLINE (1946 onwards; Appendix 3);
• Ovid Embase (1980 onwards);
• Ovid PsycINFO (1806 onwards).
We will not apply any restrictions on date, language or publication
status to the searches.
We will search international trials registries via the World Health
Organization’s trials portal ( ICTRP) and ClinicalTrials.gov to
identify unpublished or ongoing trials.
We will rerun all searches close to publication if the initial search
date is greater than 12 months. We will also search for any relevant
retraction statements and errata.
Searching other resources
Grey literature
We will search the following sources of grey literature (primarily
for dissertations and theses):
• Open Grey ( www.opengrey.eu/);
• ProQuest Dissertations & Theses Global (
www.proquest.com/products-services/pqdtglobal.html);
• DART-Europe E-theses Portal ( www.dart-europe.eu/);
• EThOS - the British Libraries e-theses online service (
ethos.bl.uk/);
• Open Acces Theses and Dissertations ( oatd.org).
Reference lists
We will check the reference lists of all included trials and relevant
systematic reviews to identify additional trials missed from the
original electronic searches (e.g. unpublished or in-press citations).
Personal communication
We will contact trial authors and subject experts for information
on unpublished or ongoing trials, or to request additional trial
data.
Data collection and analysis
Selection of studies
At least two review authors will examine the abstracts of all publi-
cations obtained through the search strategy. We will then obtain
full articles of all trials identified by any one of the review authors
and two review authors will independently assess full-texts accord-
ing to the criteria relating to characteristics of the studies, partici-
pants, and interventions. We will discuss reasons for disagreement
with a third reviewer, and contact external experts or trial authors
if necessary in order to reach agreement. We will record reasons
for excluding records at this stage. For all included studies, we
will link multiple reports from the same study. We will present
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a PRISMA flow diagram to show the process of study selection
(Moher 2009).
Data extraction and management
At least two review authors will independently extract data from
each trial. These review authors will discuss any disagreement with
an additional review author, and, when necessary, will contact the
authors of the trials for further information.
We will extract and enter into a spreadsheet information related to
trial population, sample size, interventions, comparators, potential
biases in the conduct of the trial, source of funding, outcomes
including adverse events, number needed to treat for an additional
beneficial outcome (NNTB), follow-up and methods of statistical
analysis.
Management of time points
We plan to summarise and categorise post-treatment outcomes
and outcomes at each reported follow-up point as follows: short
term (up to 6 months post-treatment), medium term (7 to 12
months post-treatment) and long term (longer than 12 months).
Assessment of risk of bias in included studies
We will assess risk of bias for each included trial using the Revised
Cochrane Collaboration’s ’Risk of bias’ tool ((RoB2); Higgins
2016), which considers the following five domains.
1. Risk of bias arising from the randomisation process,
including allocation and randomisation
2. Risk of bias due to deviations from the intended
interventions, including blinding of participants and people
delivering the interventions
3. Missing outcome data
4. Risk of bias in measurement of the outcome, including
blinding of outcome assessors
5. Selective outcome reporting
For cluster-RCTs and cross-over trials, we will use the templates
specifically designed to assess these types of trials, with the same
five domains.
In addition, we will systematically appraise the following risks of
bias, specific to psychological therapy trials.
1. Treatment fidelity: was the therapy monitored against a
manual or a scale through audiotapes or videotapes?
2. Researcher allegiance/conflict of interest: did the researcher
have a vested interest for or against the therapies under
examination?
3. Therapist allegiance/conflict of interest: did the therapist
have a vested interest for or against the therapies provided?
4. Other sources of bias: was the trial apparently free of other
problems that could put it at high risk of bias?
We will make a judgement on the risk of bias for each domain
within and across trials, and categorise this as low, unclear, or high
risk of bias.
Two review authors will independently assess the risk of bias in
selected trials and discuss any disagreements with a third review
author. Where necessary, we will contact trial authors for further
information. We will present all ’Risk of bias’ data graphically, and
narratively in the text. We will use allocation concealment as a
marker of trial quality for the purpose of undertaking sensitivity
analyses.
Measures of treatment effect
Continuous outcomes
Where trials use the same outcome measure for comparison, we
will pool data by calculating the mean difference (MD). When
trials use different measures to assess the same outcome, we will
pool data with standardised mean difference (SMD) and calculate
95% confidence intervals (95% CIs).
A SMD of zero means that the intervention and control groups
have equivalent treatment effects. We anticipate that, for most
measures, a lower score will indicate greater improvement. For ex-
ample, a lower score on depression symptom instruments indicates
an improvement in symptoms. In these cases, a SMD less than
zero indicates that the intervention has a greater effect than the
control. An SMD greater than zero indicates that the intervention
has a smaller effect than the control. Interpretation of the SMD is
reversed in cases where a greater continuous score indicates greater
improvement.
To facilitate interpretation of results in terms of their clinical rele-
vance, we will express SMDs for continuous outcomes in terms of
units on a commonly used patient-rated outcome (the Beck De-
pression Inventory (BDI)) and a commonly used clinician-rated
instrument (Hamilton Depression Rating Scale (HAM-D)). We
will calculate these re-expressed estimates according to guidance
in the Cochrane Handbook (Schünemann 2017a).
Dichotomous outcomes
We will analyse dichotomous outcomes by calculating a pooled
odds ratio (OR) and 95% CIs for each comparison. Because ORs
can be difficult to interpret, we will convert these pooled ORs to
risk ratios (RRs) using the formula provided in theCochraneHand-
book for Systematic Reviews of Interventions (Schünemann 2017a),
and we will present them in this form for ease of interpretation.
In addition, we calculated the NNTB with 95% CIs for all di-
chotomous outcomes to facilitate interpretation; this is the ex-
pected number of people who need to receive the intervention
rather than the comparator for one additional person to achieve a
beneficial outcome (Schünemann 2017a).
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If one trial uses both continuous and dichotomous variables for the
same outcome we will give preference to the continuous outcome.
If different outcomes are used, for example depression score and
clinical depression yes/no, we will report both.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials as long as proper adjust-
ment for the intracluster correlation can be conducted in accor-
dance with the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011).
Cross-over trials
We will include trials employing a cross-over design in the review,
but we will only use data from the first active treatment phase.
Trials with multiple treatment groups
Multiple-arm trials (those with more than two intervention arms)
can pose analytical problems in pair-wise meta-analysis. For trials
with more than two eligible arms, we will manage data in this
review as follows.
Multiple experimental intervention groups versus a single
control group
If studies compare multiple eligible experimental interventions
with a single control group, we will split the control group to
enable pair-wise comparisons.
One or more experimental intervention groups versus
multiple control groups
1. If studies use multiple ’active’ comparator interventions, we
will combine these comparator groups to compare to the
behavioural activation intervention group (objective 1/2).
2. If studies use multiple control groups including treatment
as usual/ waiting list/ attention placebo/ psychological placebo,
we will combine the control groups to compare to the
behavioural activation intervention group (objective 3).
Dealing with missing data
We will manage missing dichotomous data through intention-to-
treat (ITT) analysis, in which we will assume that participants
who dropped out after randomisation had a negative outcome.
We also plan to conduct best/worse case scenarios for the clinical
response outcome, in which we will assume that dropouts in the
active treatment group had positive outcomes and those in the
control group had negative outcomes (best case scenario), and that
dropouts in the active treatment group had negative outcomes
and those in the control group had positive outcomes (worst case
scenario), thus providing boundaries for the observed treatment
effect. If a large amount of information is missing, we will give
these best/worst case scenarios greater emphasis in the presentation
of results.
We will analyse missing continuous data on an endpoint basis,
including only participants with a final assessment, or by using the
last observation carried forward (LOCF) to the final assessment,
if trial authors report LOCF data. When SDs are missing, we will
attempt to obtain these data by contacting trial authors. When
SDs are not available from trial authors, we will calculate them
from P values, t-values, CIs or standard errors, if these are reported
in the articles (Deeks 1997). If SDs are missing, we will attempt
to obtain these data by contacting trial authors.
If a vastmajority of SDs are available andonly aminority of SDs are
unavailable or unobtainable, we plan to use themethod devised by
Furukawa and colleagues to impute SDs and calculate percentage
responders (da Costa 2012; Furukawa 2005; Furukawa 2006). If
we use this method, we will interpret data with caution and will
take into account the degree of observed heterogeneity. We will
also undertake a sensitivity analysis to examine the effect of the
decision to use imputed data.
If additional figures are not available or obtainable and it is not
deemed appropriate to use the Furukawa method as described
above, we will not include the trial data in the comparison of
interest.
Assessment of heterogeneity
We will formally test statistical heterogeneity using the Chi2 test,
which provides evidence of variation in effect estimates beyond
that of chance. Because the Chi2 test has low power to assess het-
erogeneity when a small number of participants or trials are in-
cluded, we will conservatively set the P value at 0.1 (Deeks 2017).
We will also quantify heterogeneity using the I2 statistic, which
calculates the percentage of variability due to heterogeneity rather
than to chance (Higgins 2003). We consider I2 statistic values in
the range of 50% to 90% to represent substantial statistical hetero-
geneity and will explored them further. However, the importance
of the observed I2 statistic depends on themagnitude and direction
of treatment effects and the strength of evidence for heterogene-
ity. Forest plots generated in Review Manager 5 (RevMan 5) will
provide an estimate of tau2, the between-trial variance in a ran-
dom-effects meta-analysis (Deeks 2017; Review Manager 2014).
To provide an indication of the spread of true intervention effects,
we will also use the tau2 estimate to determine an approximate
range of intervention effects for the primary outcome using the
method outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2017).
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Assessment of reporting biases
As far as possible, we will minimise the impact of reporting bi-
ases by undertaking comprehensive searches of multiple sources
(including trials registries), to identify unpublished material and
including non-English language publications.
We will also try to identify outcome reporting bias in trials by
recording all trial outcomes, planned and reported, and noting
where outcomes are missing. If we find evidence of missing out-
comes, we will attempt to obtain any available data directly from
the trial authors.
We plan to construct funnel plots to establish the potential influ-
ence of reporting biases and small-trial effects (Sterne 2017).
Data synthesis
We plan to conduct a meta-analysis of included trials. Given the
potential heterogeneity of behavioural activation approaches for
inclusion, together with the likelihood of differing secondary co-
morbid mental disorders in the population of interest, we will use
a random-effects model in all analyses.
Subgroup analysis and investigation of heterogeneity
Clinical heterogeneity
We plan to conduct the following subgroup analyses.
1. Patient age: old age in particular can be expected to relate to
treatment effect, as older patients are more likely to suffer
comorbidities. We plan to conduct subgroup analyses with
patients younger than 65 years and those aged 65 years or older.
2. Level of therapist: one of the often mentioned potential
benefits of less complex models of behavioural activation is that
therapies can be delivered by a therapist with less training, or
without a relevant accreditation. We expect that this analysis by
level of therapist will also account for potential differences by
intervention complexities. We will conduct subgroup analyses
with level of therapist classified as:
i) accredited/received formal training of several years
(specialist); or
ii) minimal training/lay counsellor (non-specialist)
3. Baseline depression severity: the severity of depression on
entry into the trial is expected to have an impact on outcomes.
We categorised depression severity as subthreshold depression,
mild, moderate, or severe.
4. Length of treatment: we will categorise treatment into those
delivered in one to three sessions and treatments of longer
duration. We anticipate that the length of treatment could
influence effectiveness.
5. Type of psychological therapy comparison: The type of
psychological therapy comparator used is likely to influence the
observed effectiveness of the intervention. When possible,
comparators will be categorised as psychodynamic, behavioural,
humanistic, integrative, or cognitive-behavioural.
6. Type of control comparison: The type of control
comparator used is likely to influence the observed effectiveness
of the intervention. When possible, comparators will be
categorised as waiting list, treatment as usual/usual care,
attention placebo, or psychological placebo.
Sensitivity analysis
1. Trial quality: we will exclude low- quality trials in a
sensitivity analysis, if we identify a number of higher-quality
trials. As a marker of quality, we will use the ’allocation
concealment’ criteria from the ’Risk of bias’ assessment.
2. Mode of delivery: we will exclude therapies delivered
through computer-based or electronic guidance without a
substantial face-to-face component.
3. Subthreshold depression: we will exclude trials of
subthreshold depression to determine whether our decision to
include non-clinical levels of depression has had a substantial
impact on the results.
4. Group therapy: we will exclude trials of group therapy for
behavioural activation as the mode of delivery of psychotherapy
could influence effectiveness of the therapy.
’Summary of findings’ table
We plan to construct a ’Summary of findings’ table to present the
main findings of the review. We will report the outcomes listed be-
low and present standardised effect size estimates and 95% confi-
dence intervals. Two reviewers will independently use theGRADE
approach to assess the quality of the evidence for each outcome,
and agreement will be sought between them, if necessary with help
from a third reviewer (Schünemann 2017a).We will use GRADE-
proGDT to create our ’Summary of findings’ tables (GRADEpro
2015), and follow standard methods as described in the Cochrane
Handbook for Systematic Reviews of Interventions to prepare our
’Summary of findings’ table (Schünemann 2017b). For each of
our main comparisons, the following outcomes (measured up to
24 months) will be included:
1. Treatment efficacy (number of participants responding to
treatment);
2. Treatment acceptability (number of participants who
dropped out);
3. Improvement in depression outcomes as a continuous score;
4. Quality of life;
5. Social adjustment/ functioning score;
6. Improvement in anxiety symptoms as a continuous score.
The ’Summary of findings’ table will be created before writing
our discussion, abstract, and conclusions, so that the authors can
jointly consider the potential impact of the study quality for each
outcome on themean treatment effect and our confidence in these
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findings. Our confidence in the mean treatment effects based on
the GRADE assessments will then be reflected in the interpreta-
tion of the results, which informs the abstract, lay summary, and
discussion sections of the review.
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A P P E N D I C E S
Appendix 1. Categories of psychological therapies
Categories Abbreviation Subcategories Abbreviation
1. Behavioural therapies BT Behavioural therapy (Lewinsohn)
Behavioural activation (original
model) (Jacobson)
BA
Social skills training/assertiveness
training
SST/assertion
Relaxation therapy
Other behavioural therapies
2. Cognitive-behavioural thera-
pies
CBT Cognitive therapy
Rational emotive behaviour therapy
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(Continued)
Problem-solving therapy
Self-control therapy
Coping with depression course
Other cognitive-behavioural therapies
3. Mindfulness-
based ’third wave’ cognitive and
behavioural therapies
Third wave CBT Acceptance and commitment therapy
Compassionate mind training
Functional analytic psychotherapy
Extended behavioural activation eBA
Metacognitive therapy
Mindfulness-based cognitive therapy
Dialectical behaviour therapy
Other third wave cognitive and be-
havioural therapies
(other third wave CBT)
4. Psychodynamic therapies Drive/structural model (Freud)
Relational model (Strupp, Luborsky)
Integrative analytic model (Mann)
Other psychodynamic therapies
5. Humanistic therapies Person-centered therapy (Rogerian)
Gestalt therapy
Experiential therapies
Transactional analysis
Existential therapy
Non-directive/supportive therapies
Other humanistic therapies
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(Continued)
6. Interpersonal, cognitive ana-
lytic and other integrative ther-
apies
(integrative therapies)
Interpersonal therapy IPT
Cognitive-analytic therapy CAT
Psychodynamic-interpersonal therapy
Cognitive-behavioural analysis system
of psychotherapy
Counselling
Motivational interviewing
Other integrative therapy approaches
Appendix 2. Specialised Register: CCMD-CTR
Cochrane Common Mental Disorders Controlled Trials Register (CCMD-CTR)
Cochrane CommonMental Disorders has a specialised register of randomised controlled trials, the CCMD-CTR. This register contains
over 40,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self-harm and other
mental disorders within the scope of this Group. The CCMD-CTR is a partially studies-based register with more than 50% of reference
records tagged to around 12,500 individually PICO-coded study records. Reports of trials for inclusion in the register are collated from
(weekly) generic searches of MEDLINE (1950 onwards), Embase (1974 onwards) and PsycINFO (1967 onwards), quarterly searches
of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific searches of additional databases. Reports of
trials are also sourced from international trials registries, drug companies, the handsearching of key journals, conference proceedings
and other (non-Cochrane) systematic reviews and meta-analyses. Details of CCMD’s core search strategies (used to identify RCTs) can
be found on the Group’s website, with an example of the core MEDLINE search displayed below.
The CCMD-CTR will be searched for this review using the following terms:
((“behavioral activation” or ”behavior therapy“ or “behavior modification” or “self-monitoring” or “self-management therapy” or “self-control
therapy” or “task assignment”):SIN and (depress*):SCO)
N.B. The search of the CCMD-CTR will only retrieve RCTs of ’behavioural activation’, or the main elements of behavioural activation
in participants with clinically diagnosed depression, hence additional searches of the main bibliographic databases (all years to date) to
identify trials which also include participants with subthreshold depression.
The search strategy listed below is the weekly OVID Medline search which was used to inform the Group’s specialised register.
It is based on a list of terms for all conditions within the scope of the Cochrane Common Mental Disorders Group plus a
sensitive RCT filter.
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or agoraphobia/
or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ or anxiety/ or anxiety,
castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic disorders/
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or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ ormunchausen syndrome by proxy/ ormunchausen syndrome/
or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control disorders/
or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual dysfunctions,
psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic*
or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or
agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#
ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen
or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental
health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomised controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or
place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or
study or studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomised controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental
or random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records are screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of
RCTs are tagged to the appropriate study record.
The CCMD-CTR is current to June 2016 only.
Appendix 3. MEDLINE search (behavioural activation)
TheOvidMEDLINE databases will be searched (all years to date) using the following terms to identify RCTs of ’behavioural activation’,
or the main elements of behavioural activation, in participants with clinically diagnosed or subthreshold depression.
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to onwards>
Search Strategy:
--------------------------------------------------------------------------------
1 ((behavio* adj1 activat*) or BATD).ti,ab,kf.
2 (behavio* adj3 (reinforce* or re-inforce*)).ti,ab,kf.
3 (behavio* adj2 (contracting or modification or modify*)).ti,ab,kf.
4 reinforc*.ti,kf. or (((positive or contingent) adj1 reinforc*) or (reinforc* adj3 (environment* or experience*))).ti,ab,kf.
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2
6 (activit* adj2 schedul*).ti,ab,kf.
7 ((pleas* or enjoyable or rewarding) adj (activit* or event?)).ti,ab,kf.
8 (operant conditioning or instrumental learning).ti,ab,kf.
9 (positive interaction* or avoidant coping or environmental contingenc* or contigency management).ti,ab,kf.
10 functional analysis.ti,ab,kf.
11 behavio*.mp. and (self adj (evaluat* or monitor*)).ti,ab,kf.
12 ((gain? or reapprais*) adj2 focus*).ti,ab,kf.
13 ((psychoeducat* or psycho-educat*) and (coping behavi* or coping skills or self manag* or (behavi* adj2 chang*))).ti,ab,kf,hw.
14 or/1-13
15 Behavior Therapy/ and depress*.ti,hw.
16 (behavio* therapy adj3 depress*).ti,ab,kf.
17 ((behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)) and depress*).ti,kf.
18 or/15-17
19 Depression/
20 Depressive Disorder/ or Depressive Disorder, Major/
21 depress*.ti,ab,kf.
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22 (mood? or mental health or ((emotion* or psychological) adj (distress or trauma*))).ti,kf.
23 or/19-22
24 (14 and 23) or 18
25 controlled clinical trial.pt.
26 randomized controlled trial.pt.
27 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf.
28 (RCT or “at random” or (random* adj3 (administ* or allocat* or assign* or class* or cluster or control* or determine* or divide* or
division or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or subsitut* or treat*))).ti,ab,kf.
29 trial.ab,ti,kf.
30 (control* and (trial or study or group*) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kf,hw.
31 ((allocat* or assign* or receive*) and (placebo or no-treatment or waitlist or wait* list* or ((treatment or care) adj2 usual)) and
(control or group)).ab.
32 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,kf.
33 double-blind method/ or random allocation/ or single-blind method/
34 exp animals/ not humans.sh.
35 (or/25-33) not 34
36 24 and 35
37 review.pt.
38 case reports.pt.
39 ((child* or adolescent* or infant* or p?ediatr*) not adult?).ti.
40 36 not (or/37-39)
***************************
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